Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
Introduction to Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market
The Asia-Pacific next-generation breast cancer diagnostic and screening market was valued at $554.3 million in 2023 and is anticipated to reach $1,779.4 million by 2032. The anticipated growth in the next-generation breast cancer diagnostic and screening market is projected to be fueled by several factors. These include the uptick in the occurrence of breast cancer cases, heightened awareness concerning early detection of breast cancer, a growing emphasis on breast cancer biomarkers for improved screening, prognosis, and tailored treatment, as well as the escalation in partnerships and collaborations among industry participants.
Market Introduction
The Asia-Pacific (APAC) region anticipates significant growth in the next-generation breast cancer diagnostic and screening market. This growth is propelled by various factors, including the increasing incidence of breast cancer cases in the region. Heightened awareness campaigns focusing on early detection and screening contribute to this surge. Additionally, there's a growing emphasis on utilizing breast cancer biomarkers for more effective screening, prognosis, and personalized treatment strategies. Moreover, the collaborative efforts and partnerships among market players further drive advancements in diagnostic technologies and screening methodologies. With these dynamics in play, the APAC next-generation breast cancer diagnostic and screening market presents promising opportunities for improved breast cancer management and outcomes across the region.
Market Segmentation
Segmentation 1: by Country
Japan
China
India
Australia
South Korea
Singapore
Rest-of-Asia-Pacific
How can this report add value to an organization?
Growth/Marketing Strategy: The APAC next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the APAC next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.
Competitive Strategy: Key players in the APAC next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 1-5 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of the Study
- Research Methodology
- 1 Oncology Molecular Diagnostic Market
- 1.1 Overview
- 1.2 Cancer Type
- 1.3 Technology
- 1.4 Market Dynamics
- 1.5 Regulatory-Approved Products
- 2 Next-Generation Breast Cancer Diagnostic and Screening Market
- 2.1 Market Outlook
- 2.1.1 Product Definition
- 2.1.2 Definition by Technologies Involved
- 2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
- 2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
- 2.1.2.3 Next-Generation Sequencing
- 2.1.2.4 Immunohistochemistry (IHC)
- 2.1.3 Inclusion and Exclusion
- 2.1.4 Overview
- 2.1.4.1 Market Size and Growth Potential, $Million, 2022-2032
- 3 Industry Outlook
- 3.1 Key Trends
- 3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
- 3.1.2 Complete Automation of Next-Generation Techniques
- 3.2 Regulatory Framework
- 3.2.1 Regulatory Framework in the U.S.
- 3.2.1.1 FDA Regulation
- 3.2.1.2 CMS Regulations (Reimbursement Scenario)
- 3.2.2 Regulatory Framework in Europe
- 3.2.3 Regulatory Framework in Asia-Pacific
- 3.2.3.1 China
- 3.2.3.2 Japan
- 3.3 Regulatory-Approved Products
- 3.4 Clinical Trials
- 3.5 Breast Cancer Incidence Growth Rates (by Country)
- 3.6 Advantages and Limitations of Different Techniques
- 3.7 Pricing
- 4 Regions
- 4.1 Asia-Pacific
- 4.1.1 Key Findings
- 4.1.2 Market Dynamics
- 4.1.2.1 Impact Analysis
- 4.1.3 Market Sizing and Forecast
- 4.1.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 4.1.3.1.1 China
- 4.1.3.1.1.1 Market Dynamics
- 4.1.3.1.1.2 Market Sizing and Forecast
- 4.1.3.1.2 Japan
- 4.1.3.1.2.1 Market Dynamics
- 4.1.3.1.2.2 Market Sizing and Forecast
- 4.1.3.1.3 India
- 4.1.3.1.3.1 Market Dynamics
- 4.1.3.1.3.2 Market Sizing and Forecast
- 4.1.3.1.4 Australia
- 4.1.3.1.4.1 Market Dynamics
- 4.1.3.1.4.2 Market Sizing and Forecast
- 4.1.3.1.5 South Korea
- 4.1.3.1.5.1 Market Dynamics
- 4.1.3.1.5.2 Market Sizing and Forecast
- 4.1.3.1.6 Singapore
- 4.1.3.1.6.1 Market Dynamics
- 4.1.3.1.6.2 Market Sizing and Forecast
- 4.1.3.1.7 Rest-of-Asia-Pacific
- 4.1.3.1.7.1 Market Dynamics
- 4.1.3.1.7.2 Market Sizing and Forecast
- 5 Markets - Competitive Benchmarking
- 5.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- 5.2 Company Profiles
- 5.2.1 BGI Genomics Co., Ltd.
- 5.2.1.1 Company Overview
- 5.2.1.2 Role of BGI Genomics Co., Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
- 5.2.1.3 Financials
- 5.2.1.4 Recent Developments
- 5.2.1.5 Analyst Perception
- List of Figures
- Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
- Figure 2: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 3: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology), $Million, 2022 and 2032
- Figure 4: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker), $Million, 2022 and 2032
- Figure 5: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type), $Million, 2022 and 2032
- Figure 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering), $Million, 2022 and 2032
- Figure 7: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), $Million, 2022 and 2032
- Figure 8: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Figure 9: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
- Figure 10: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
- Figure 11: Primary Research Methodology
- Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 13: Top-Down Approach (Segment-Wise Analysis)
- Figure 14: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
- Figure 15: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
- Figure 16: Oncology Molecular Diagnostic Market, Market Dynamics
- Figure 17: Next-Generation Breast Cancer Diagnostic and Screening Market, Size and Growth Potential, $Million, 2022-2032
- Figure 18: Market Size and Growth Potential (by Region), $Million, 2022-2032
- Figure 19: FDA Guidelines for CDx Approval
- Figure 20: Criteria for CMS Coverage/Reimbursement
- Figure 21: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
- Figure 22: Breast Cancer Incidence Growth Rates (by Country), 2020 and 2040
- Figure 23: Advantages and Limitations of Different Techniques in the Next-Generation Breast Cancer Diagnostic and Screening Market
- Figure 24: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
- Figure 25: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 26: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 27: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 28: China Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 29: Japan Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 30: India Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 31: Australia Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 32: South Korea Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 33: Singapore Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 34: Rest-of-Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 35: BGI Genomics Co., Ltd. Product Portfolio
- Figure 36: BGI Genomics Co., Ltd.: Overall Financials, $Million, 2020-2022
- List of Tables
- Table 1: Key Questions Answered in the Report
- Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
- Table 3: Some of the Regulatory-Approved Next-Generation Breast Cancer Diagnostic and Screening Products/Tests
- Table 4: Next-Generation Breast Cancer Diagnostic and Screening, Clinical Trials
- Table 5: Pricing of Some Products/Services for Next-Generation Breast Cancer Diagnostic and Screening
- Table 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 7: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- Table 8: BGI Genomics Co. Ltd.: Key Products and Features
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook